Thu, May 15, 9:06 PM (34 days ago)
**NRX Pharmaceuticals, Inc. (NRXP) Q1 2025 Financial Summary** **Financial Health and Performance:** - **Revenue:** No revenue generated. - **Net Loss:** $5.5 million for Q1 2025, compared to $6.5 million in Q1 2024. - **Operating Expenses:** $3.8 million in Q1 2025, down from $6.0 million in Q1 2024. - **Research & Development:** $0.8 million in Q1 2025, down from $1.7 million in Q1 2024. - **General & Administrative:** $2.9 million in Q1 2025, down from $4.3 million in Q1 2024. - **Settlement Expense:** $0.1 million in Q1 2025, none in Q1 2024. - **Cash Position:** $5.5 million in cash and cash equivalents as of March 31, 2025. - **Stockholders' Deficit:** $25.2 million as of March 31, 2025. - **Working Capital Deficit:** $25.5 million as of March 31, 2025. **Key Financial Metrics:** - **Earnings per Share (EPS):** Basic and diluted loss per share of $0.34 for Q1 2025, compared to $0.74 in Q1 2024. - **Weighted Average Common Shares Outstanding:** 16.4 million for Q1 2025, up from 8.9 million in Q1 2024. **Cash Flow:** - **Operating Activities:** Net cash used of $3.5 million in Q1 2025, compared to $3.7 million in Q1 2024. - **Financing Activities:** Net cash provided of $7.6 million in Q1 2025, compared to $0.4 million in Q1 2024. - **Net Increase in Cash:** $4.1 million in Q1 2025, compared to a decrease of $3.3 million in Q1 2024. **Debt and Equity:** - **Convertible Notes:** $8.4 million in convertible notes payable as of March 31, 2025. - **Warrant Liabilities:** $9.9 million in warrant liabilities as of March 31, 2025. - **Equity Offerings:** Completed a registered direct offering raising $3.5 million in Q1 2025. **Uncertainties and Future Operations:** - **Going Concern:** Substantial doubt exists regarding the company's ability to continue as a going concern for at least twelve months from March 31, 2025. - **Future Financing:** Plans to pursue additional equity or debt financing in 2025 to support operations and meet debt obligations. - **Clinical Trials:** Awaiting FDA approval for NRX-100 and NRX-101, with anticipated PDUFA dates by year-end 2025. - **HOPE Therapeutics:** Expansion plans include acquiring clinics and achieving $100 million in pro-forma revenues by year-end 2025. **Trends:** - **Cost Reduction:** Significant decrease in operating expenses driven by cost-cutting measures. - **Cash Management:** Improved cash position through strategic financing and cost management. - **Operational Focus:** Shift towards revenue-generating activities through HOPE Therapeutics and clinical trial progress. **Summary:** NRX Pharmaceuticals continues to face financial challenges but has made strides in reducing operating expenses and improving its cash position. The company is focused on securing additional financing, advancing clinical trials, and expanding its HOPE Therapeutics subsidiary to achieve revenue growth. Despite uncertainties, NRXP is positioning itself for potential growth and operational sustainability.